Non-HDL Cholesterol

Non-HDL cholesterol represents the total cholesterol contained inside all potentially harmful lipoprotein particles circulating in your bloodstream. It’s calculated as Total Cholesterol − HDL Cholesterol, which means it includes cholesterol carried by LDL, VLDL, IDL, triglyceride-rich remnant particles, and lipoprotein(a)—in other words, “everything except HDL.” Because it captures multiple particle types, non-HDL cholesterol is often described as a way of counting all the “bad actors” in one number.

A major advantage is that non-HDL cholesterol does not require fasting, and it remains reliable even when triglycerides are high, a situation where calculated LDL can become less accurate. This makes non-HDL especially useful in people with patterns like metabolic syndrome, insulin resistance, type 2 diabetes, obesity, or elevated triglycerides, where cardiovascular risk can be underestimated if you look only at LDL cholesterol.

Importantly, the particles included in non-HDL cholesterol share a common feature: each carries apolipoprotein B (apoB). For that reason, non-HDL cholesterol often tracks closely with apoB and can act as a practical estimate of the total burden of atherogenic particles repeatedly passing through (and potentially entering) the artery wall. Major guidelines and expert groups recognise non-HDL cholesterol as a key target alongside LDL cholesterol for cardiovascular risk assessment and management.

Non-HDL cholesterol is now widely recognised as a strong predictor of cardiovascular disease (CVD) — including heart attack, stroke, peripheral artery disease, and cardiovascular mortality — and in many studies it outperforms LDL cholesterol alone. The reason is straightforward: LDL is only one type of atherogenic particle, while non-HDL includes LDL plus other apoB-containing particles that can also contribute to plaque formation.

From a functional & integrative lens, non-HDL cholesterol reflects the total cholesterol load being delivered by atherogenic particles over time. Cardiovascular disease risk is not just about a single “snapshot” result — it’s strongly influenced by cumulative exposure across decades. Large cohort data show that long-term event rates rise progressively across non-HDL cholesterol categories, highlighting that higher levels generally mean greater lifetime arterial exposure to atherogenic particles and therefore higher long-term risk.

A key reason non-HDL cholesterol can be more informative — especially in metabolic health patterns — is that it includes cholesterol carried by triglyceride-rich lipoproteins and their remnants. These remnant particles can enter the artery wall similarly to LDL, where cholesterol can become trapped and contribute to inflammatory plaque development. This matters because in insulin resistance and related states, the liver often produces more VLDL and remnants, raising non-HDL cholesterol even when LDL appears “fine.”

Non-HDL cholesterol can also help identify residual risk — the risk that remains even when LDL cholesterol looks controlled. Studies in statin-treated populations show that non-HDL cholesterol (and apoB) can continue to predict cardiovascular risk when LDL cholesterol alone is less informative. This is one reason many expert groups emphasise non-HDL cholesterol as an important marker for prevention decisions — particularly when triglycerides are elevated or when overall metabolic risk is higher.

Dietary factors can meaningfully shift non-HDL cholesterol — especially the type and quality of fats and carbohydrates you eat. Saturated fats and trans fats can raise LDL and non-HDL cholesterol, while replacing saturated fats with unsaturated fats (polyunsaturated and monounsaturated fats) can improve the lipid profile. Dietary cholesterol can also raise blood cholesterol, although its effect tends to be smaller and more variable between individuals. On the protective side, viscous soluble fibre (e.g., oats, barley, legumes, apples, citrus, psyllium) can lower LDL and non-HDL cholesterol by reducing cholesterol reabsorption, and plant sterols/stanols (about 2 g/day, commonly via fortified foods) can reduce cholesterol absorption and lower LDL and non-HDL cholesterol. Refined carbohydrates and added sugars can worsen lipid patterns in some people — particularly those with insulin resistance — by raising triglycerides and VLDL production, which increases non-HDL cholesterol.

Lifestyle factors influence non-HDL cholesterol both directly and indirectly. Regular physical activity improves lipid profiles (often with modest LDL/non-HDL reductions but meaningful improvements in triglycerides, HDL, insulin sensitivity, blood pressure, and endothelial function). Weight loss for people with obesity typically lowers LDL and non-HDL cholesterol in proportion to the amount lost, with broader cardiometabolic benefits. Smoking worsens lipid health and strongly compounds cardiovascular risk, making cessation a high-impact lever. Alcohol can raise triglycerides and VLDL when intake is excessive, contributing to higher non-HDL cholesterol. Sleep and stress patterns can also influence metabolic health and lipid regulation through hormonal and inflammatory pathways.

Related biomarkers and conditions often move together with non-HDL cholesterol. Higher triglycerides raise VLDL and remnants, directly increasing non-HDL cholesterol. Low HDL and elevated non-HDL can cluster in metabolic syndrome. ApoB parallels non-HDL cholesterol because it reflects the number of atherogenic particles. Insulin resistance can increase VLDL production and impair clearance of triglyceride-rich particles, raising non-HDL cholesterol even when LDL doesn’t look alarming. Hypothyroidism can elevate LDL and non-HDL cholesterol by reducing lipoprotein clearance, and some medications can shift lipid patterns.

If your results are high

If your non-HDL cholesterol is elevated, lifestyle foundations are the core strategy, and targets should be personalised with your healthcare provider based on overall risk (including family history and conditions like diabetes).

Diet:

• (focus on lowering atherogenic particles): Emphasise a Mediterranean/DASH-style pattern with plenty of vegetables and minimally processed whole foods.

• Reduce saturated fat by limiting full-fat dairy, fatty/processed meats, butter, and certain tropical oils; and avoid trans fats (partially hydrogenated oils).

• Replace these with unsaturated fats: extra-virgin olive oil (2–3 tablespoons/day), nuts (≈¼ cup/day), seeds (2–3 tablespoons/day), avocado (½–1/day), and fatty fish (≈4 oz, at least 2–3 times/week).

• Add cholesterol-lowering components: viscous soluble fibre (aiming 10–25 g/day) using oats, barley, legumes, apples/citrus, and psyllium where appropriate; and plant sterols/stanols (~2 g/day) using fortified foods when available.

• Reduce refined carbohydrates and added sugars (especially if triglycerides are elevated).

Lifestyle:

• Aim for 150–300 minutes/week of moderate aerobic activity (or 75–150 minutes/week vigorous) plus resistance training ≥2 days/week.

• If you have overweight/obesity, a 5–10% body-weight reduction commonly improves non-HDL cholesterol and broader metabolic risk.

• Prioritise smoking cessation if relevant.

• Keep alcohol within moderate ranges (excess intake can raise triglycerides and non-HDL cholesterol).

• Support sleep (7–9 hours/night) and stress management to reinforce metabolic health.

Supplements (adjuncts consistent with the guide): Consider psyllium fibre and/or plant sterols/stanols if you struggle to reach effective intakes through food, ideally in a structured plan with your clinician.

Additional tests:

• to consider (to clarify the “why”): Discuss checking triglycerides

• apoB

• lipoprotein(a) (since these particles contribute to non-HDL cholesterol). If clinically relevant

• consider evaluation for metabolic drivers like insulin resistance/diabetes and for thyroid dysfunction

• which can raise non-HDL cholesterol

If your results are low

Low non-HDL cholesterol is generally a sign that your atherogenic particle cholesterol burden is low.

Diet: Continue a whole-food pattern emphasising vegetables, fruits, whole grains, legumes, and healthy fats (olive oil, nuts, seeds, fish).

Lifestyle: Maintain regular physical activity and healthy body weight; avoid smoking.

Supplements: No specific supplements are indicated solely to raise non-HDL cholesterol.

Additional tests to consider: Routine lipid monitoring as advised by your healthcare provider.

1. Nordestgaard BG. A test in context: Lipid profile, fasting versus nonfasting. Journal of the American College of Cardiology. 2017;70(13):1637–1646. doi:10.1016/j.jacc.2017.08.006

2. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk. Journal of the American College of Cardiology. 2022;80(14):1366–1418. doi:10.1016/j.jacc.2022.07.006

3. Bays HE, Jones PH, Brown WV, Jacobson TA. National Lipid Association annual summary of clinical lipidology 2015. Journal of Clinical Lipidology. 2014;8(6 Suppl):S1–S36. doi:10.1016/j.jacl.2014.10.002

4. Brunner FJ, Waldeyer C, Ojeda F, et al. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: Results from the Multinational Cardiovascular Risk Consortium. The Lancet. 2019;394(10215):2173–2183. doi:10.1016/S0140-6736(19)32519-X

5. Elshazly MB, Martin SS, Blaha MJ, et al. Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults: The VLDL-2 Study. Journal of the American College of Cardiology. 2013;62(21):1960–1965. doi:10.1016/j.jacc.2013.07.045

6. Raja V, Aguiar C, Alsayed N, et al. Non-HDL cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook. Atherosclerosis. 2023;383:117312. doi:10.1016/j.atherosclerosis.2023.117312

7. Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. Journal of the American College of Cardiology. 2021;77(11):1439–1450. doi:10.1016/j.jacc.2021.01.027

8. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association. Circulation. 2011;123(20):2292–2333. doi:10.1161/CIR.0b013e3182160726

9. Pinart M, Jeran S, Boeing H, et al. Dietary macronutrient composition in relation to circulating HDL and non-HDL cholesterol: A federated individual-level analysis. The Journal of Nutrition. 2021;151(8):2317–2329. doi:10.1093/jn/nxab077

10. Kirkpatrick CF, Sikand G, Petersen KS, et al. Nutrition interventions for adults with dyslipidemia: A clinical perspective from the National Lipid Association. Journal of Clinical Lipidology. 2023;17(4):428–451. doi:10.1016/j.jacl.2023.05.099

11. Kwon YJ, Lee S, Lee HS, Lee JW. Differing nutrient intake and dietary patterns according to the presence of hyper-LDL cholesterolemia or hypertriglyceridemia. Nutrients. 2021;13(9):3008. doi:10.3390/nu13093008

12. Freeman AM, Morris PB, Barnard N, et al. Trending cardiovascular nutrition controversies. Journal of the American College of Cardiology. 2017;69(9):1172–1187. doi:10.1016/j.jacc.2016.10.086

13. Antoniazzi L, Arroyo-Olivares R, Bittencourt MS, et al. Association of dietary components with dyslipidemia and low-grade inflammation biomarkers in adults with heterozygous familial hypercholesterolemia. European Journal of Clinical Nutrition. 2019;73(12):1622–1625. doi:10.1038/s41430-019-0529-3

14. Kirkpatrick CF, Bolick JP, Kris-Etherton PM, et al. Review of current evidence and clinical recommendations on low-carbohydrate and very-low-carbohydrate diets. Journal of Clinical Lipidology. 2019;13(5):689–711.e1. doi:10.1016/j.jacl.2019.08.003

15. Newman CB, Blaha MJ, Boord JB, et al. Lipid management in patients with endocrine disorders: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2020;105(12):dgaa674. doi:10.1210/clinem/dgaa674

16. Berisha H, Hattab R, Comi L, et al. Nutrition and lifestyle interventions in managing dyslipidemia and cardiometabolic risk. Nutrients. 2025;17(5):776. doi:10.3390/nu17050776

17. Michos ED, McEvoy JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease. The New England Journal of Medicine. 2019;381(16):1557–1567. doi:10.1056/NEJMra1806939

18. Jacobson TA, Maki KC, Orringer CE, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 2. Journal of Clinical Lipidology. 2015;9(6 Suppl):S1–S122.e1. doi:10.1016/j.jacl.2015.09.002

19. Mechanick JI, Farkouh ME, Newman JD, Garvey WT. Cardiometabolic-based chronic disease: Addressing knowledge and clinical practice gaps. Journal of the American College of Cardiology. 2020;75(5):539–555. doi:10.1016/j.jacc.2019.11.046